− Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal…
Tokyo, Japan CHARLOTTE, N.C.--(BUSINESS WIRE)--SEE (NYSE: SEE) will participate in the following event. Ted Doheny, President and CEO, and members…
— Application Includes Data from Phase 3 FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive…
WILMINGTON, Del.--(BUSINESS WIRE)--CSC, a leading provider of business, legal, tax, and digital brand services, announced today the acquisition of Eddystone…
Wipro’s first testing facility in the U.S., the Center will offer clients advanced 5G testing capabilities as well as mission-critical…
BEAVERTON, Ore.--(BUSINESS WIRE)--WiSA Technologies, Inc. (NASDAQ: WISA), a leading provider of immersive, wireless sound technology, and Sunplus Technology Co., Ltd.…
Delivering unprecedented realism, superior readiness and maximum value to the warfighter SAN DIEGO--(BUSINESS WIRE)--#CMPS--Cubic Defense was awarded a contract with…
With its lively and family-friendly atmosphere, Central Pattaya draws Russian visitors to the shopping event of the year until July…
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is…
Australia-based Phase 2a clinical study to evaluate broad-spectrum influenza vaccine candidate, OVX836 in combination with Quadrivalent Influenza Vaccines (QIVs) An…